Could neoadjuvant immunotherapy be considered part of the standard of care for patients with mismatch repair deficient (dMMR) colon cancer?
Credit available for this activity expires: 5/1/27
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/practical-community-colorectal-cancer-clinic-aligning-2026a1000dw7?ecd=bdc_podcast_libsyn_mscpedu